Regeneron Pharmaceuticals Inc. Takes $931,000 Position in Adicet Bio, Inc. (NASDAQ:ACET)

Regeneron Pharmaceuticals Inc. purchased a new stake in Adicet Bio, Inc. (NASDAQ:ACET - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 968,183 shares of the company's stock, valued at approximately $931,000. Adicet Bio makes up 0.1% of Regeneron Pharmaceuticals Inc.'s investment portfolio, making the stock its 4th biggest holding. Regeneron Pharmaceuticals Inc. owned about 1.17% of Adicet Bio at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in ACET. GSA Capital Partners LLP grew its position in shares of Adicet Bio by 161.3% in the third quarter. GSA Capital Partners LLP now owns 39,208 shares of the company's stock valued at $56,000 after purchasing an additional 24,203 shares in the last quarter. FMR LLC grew its position in shares of Adicet Bio by 31.3% in the third quarter. FMR LLC now owns 276,169 shares of the company's stock valued at $398,000 after purchasing an additional 65,903 shares in the last quarter. RBF Capital LLC grew its position in shares of Adicet Bio by 62.5% in the third quarter. RBF Capital LLC now owns 601,135 shares of the company's stock valued at $866,000 after purchasing an additional 231,135 shares in the last quarter. XTX Topco Ltd grew its position in shares of Adicet Bio by 12.5% in the third quarter. XTX Topco Ltd now owns 292,180 shares of the company's stock valued at $421,000 after purchasing an additional 32,392 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Adicet Bio by 14.5% in the third quarter. Geode Capital Management LLC now owns 768,566 shares of the company's stock valued at $1,107,000 after purchasing an additional 97,567 shares in the last quarter. 83.89% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Adicet Bio Price Performance

ACET stock traded up $0.03 during mid-day trading on Tuesday, hitting $0.79. 175,913 shares of the stock were exchanged, compared to its average volume of 860,602. The business has a fifty day moving average price of $0.92 and a 200 day moving average price of $1.14. Adicet Bio, Inc. has a 12 month low of $0.74 and a 12 month high of $2.48. The stock has a market capitalization of $64.99 million, a price-to-earnings ratio of -0.46 and a beta of 1.97.

Adicet Bio (NASDAQ:ACET - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.05. As a group, equities analysts forecast that Adicet Bio, Inc. will post -1.39 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ACET shares. JMP Securities reissued a "market perform" rating on shares of Adicet Bio in a research note on Thursday, February 6th. StockNews.com lowered Adicet Bio from a "hold" rating to a "sell" rating in a research note on Tuesday, November 19th. Finally, HC Wainwright reissued a "neutral" rating on shares of Adicet Bio in a research note on Friday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $7.50.

Adicet Bio Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.